Zygel, an experimental cannabidiol gel developed by Zynerba Pharmaceuticals to ease abnormal behaviors in people with fragile X syndrome, was well tolerated and effective, including in patients with severe disease, according to a new interim analysis of an open-label extension study. The poster, titled “Long-Term Safety and Sustained Efficacy…
The European Commission has granted orphan drug designation to Zygel, Zynerba Pharmaceuticals’ cannabidiol (CBD) transdermal gel candidate to treat for behavioral symptoms in people with fragile X syndrome. Orphan designation is assigned to promising therapies for life-threatening, rare diseases affecting fewer than 5 in every 10,000 people in…
Zygel, an experimental cannabidiol gel that Zynerba Pharmaceuticals is developing to help normalize behaviors in people with fragile X syndrome, continues to be well tolerated up to a median treatment length of 21 months, according to new data from the open-label extension of the Phase 2/3 CONNECT-FX trial.
Get regular updates to your inbox.